当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
DENGVAXIA, Dengue Tetravalent Vaccine, Live
药品名称
DENGVAXIA, Dengue Tetravalent Vaccine, Live
承诺描述
To establish a pregnancy registry for DENGVAXIA in the United States to prospectively collect data on spontaneously reported exposures to DENGVAXIA at any time during pregnancy. You will submit annual reports as well as a 5-year summary report, after which you will continue enrolling patients in the registry and submitting annual reports pending CBER review of the reports and determination that the registry can be discontinued.